{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:48:10Z","timestamp":1755218890721,"version":"3.43.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To analyze the symptoms and severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (pwMS) on disease-modifying therapies using data from the COVID-19 in multiple sclerosis (MS) Global Data Sharing Initiative dataset.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The open-access COVID-19 in MS Global Data Sharing Initiative dataset was obtained through credentialed access using PhysioNet. The variables analyzed included BMI, symptoms of COVID-19, age, current use of disease-modifying therapy (DMT), efficacy of DMT, comorbidities, hospitalization status, and type of MS. A linear regression analysis was completed. Data analysis and visualization were completed using STATA <jats:italic toggle=\"yes\">v15<\/jats:italic>, R-Studio <jats:italic toggle=\"yes\">v1.1.447<\/jats:italic>, Python <jats:italic toggle=\"yes\">v3.8,<\/jats:italic> and its associated libraries, including NumPy, Pandas, and Matplotlib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 1141 participants were included in the analysis. 904 women and 237 men were diagnosed with MS. Among the pwMS included in the study; 208 (19.54%) had a suspected infection with COVID-19 and only 49 (5.25%) were confirmed. Any COVID-19 symptom was present in 360 individuals. The commonly reported DMT agents included dimethyl fumarate (12.71%) and fingolimod (10.17%). 101 in total (8.85%) reported not using any DMT. Factors associated with hospitalization and\/or admission to the ICU included having any comorbidity (<jats:italic toggle=\"yes\">P=<\/jats:italic>0.01), neuromuscular disorder (<jats:italic toggle=\"yes\">P=<\/jats:italic>0.046), hypertension (<jats:italic toggle=\"yes\">P=<\/jats:italic>0.005), chronic kidney disease (<jats:italic toggle=\"yes\">P&lt;<\/jats:italic>0.001), and immunodeficiency (<jats:italic toggle=\"yes\">P=<\/jats:italic>0.003). The type of MS, the duration of the disease, and high-efficacy DMT therapy did not have a statistically significant influence on hospitalization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study underscores the importance of comorbidities, especially neuromuscular disorders, hypertension, chronic kidney disease, and immunodeficiencies, as possible prognostic indicators for worse outcomes of COVID-19 in pwMS. On the contrary, the type of MS, the duration of the disease, and the efficacy of disease-modifying therapy did not significantly affect the severity of the symptoms of COVID-19 in this cohort.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000001676","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T17:36:04Z","timestamp":1707154564000},"page":"720-725","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic indicators for hospitalization and ICU admission in people with multiple sclerosis and COVID-19: an analysis of the COVID-19 in MS global data sharing initiative dataset"],"prefix":"10.1097","volume":"86","author":[{"given":"Maria A.","family":"Garcia-Dominguez","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Massachusetts Chan Medical School, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Kipkorir","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Nairobi, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahadar S.","family":"Srichawla","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Massachusetts Chan Medical School, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"115321","DOI":"10.1016\/j.biopha.2023.115321","article-title":"Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases","volume":"166","author":"Tanzadehpanah","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1111\/ene.15554","article-title":"Signs and symptoms of COVID-19 in patients with multiple sclerosis","volume":"29","author":"Schiavetti","year":"2022","journal-title":"Eur J Neurol"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51408","article-title":"DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France","volume":"8","author":"Sormani","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1161\/01.CIR.101.23.e215","article-title":"PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals","volume":"101","author":"Goldberger","year":"2000","journal-title":"Circulation"},{"key":"R9-20250806","article-title":"Patient-level dataset to study the effect of COVID-19 in people with Multiple Sclerosis (version 1.0.0)","author":"Khan","year":"2023","journal-title":"PhysioNet"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458520941485","article-title":"COVID-19 in people with multiple sclerosis: a global data sharing initiative","volume":"26","author":"Peeters","year":"2020","journal-title":"Mult Scler"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/WNL.0000000000009566","article-title":"COVID-19 and neuromuscular disorders","volume":"94","author":"Guidon","year":"2020","journal-title":"Neurology"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40292-022-00506-9","article-title":"Hypertension and COVID-19: current evidence and perspectives","volume":"29","author":"Gallo","year":"2022","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5507\/bp.2020.033","article-title":"Multiple sclerosis and COVID-19","volume":"164","author":"Mares","year":"2020","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1111\/ene.14555","article-title":"Multiple sclerosis and COVID-19: How many are at risk?","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur J Neurol"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"117147","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J Neurol Sci"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s40001-022-00824-7","article-title":"COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review","volume":"27","author":"SeyedAlinaghi","year":"2022","journal-title":"Eur J Med Res"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"100470","DOI":"10.1016\/j.bbih.2022.100470","article-title":"Risk of serious infections in multiple sclerosis patients by disease course and disability status: results from a Swedish register-based study","volume":"22","author":"Brand","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"e2319766","DOI":"10.1001\/jamanetworkopen.2023.19766","article-title":"Association between Anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis","volume":"6","author":"Januel","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12883-022-02590-9","article-title":"Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study","volume":"22","author":"Etemadifar","year":"2022","journal-title":"BMC Neurol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:15:18Z","timestamp":1754486118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001676","relation":{},"ISSN":["2049-0801"],"issn-type":[{"type":"electronic","value":"2049-0801"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"2023-08-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}